Search Results
JEL Code: L65

146,452 Total downloads

Viewing: 1 - 50 of 693 papers

1.

Drugged Out: How Cognitive Bias Hurts Drug Innovation

51 San Diego Law Review 419 (2014)
Number of pages: 90 Posted: 01 Sep 2013 Last Revised: 09 Aug 2014
Accepted Paper Series
Loyola University of Chicago School of Law
Downloads 11,220
2.

Killer Acquisitions

Journal of Political Economy, Vol. 129, No. 3, pp. 649–702, March 2021
Number of pages: 97 Posted: 12 Sep 2018 Last Revised: 02 May 2021
Accepted Paper Series
London Business School, Yale School of Management and Yale School of Management
Downloads 6,933
3.

The Effects of Service Quality and Word of Mouth on Customer Acquisition, Retention and Usage

Number of pages: 48 Posted: 11 Mar 2007
Working Paper Series
City University of Hong Kong, University of Michigan, Stephen M. Ross School of Business and University of Chicago
Downloads 4,011
4.

Unpatentable Drugs and the Standards of Patentability

Texas Law Review, Vol. 87, pp. 503-570, 2009
Number of pages: 68 Posted: 04 May 2008 Last Revised: 02 Jun 2013
Accepted Paper Series
affiliation not provided to SSRN
Downloads 1,965
5.

Pharmaceutical Development Phases: A Duration Analysis

FTC, Bureau of Economics Working Paper No. 274
Number of pages: 30 Posted: 25 Oct 2004
Working Paper Series
The Brattle Group, CBO and The Brattle Group
Downloads 1,303
6.

The Great Global Vitamins Cartels

Number of pages: 190 Posted: 28 Feb 2006 Last Revised: 15 May 2008
Working Paper Series
Purdue UniversityAmerican Antitrust Institute (AAI)
Downloads 1,243
7.

The Doha Round's Public Health Legacy: Strategies for the Production and Diffusion of Patented Medicines Under the Amended TRIPS Provisions

Journal of International Economic Law, Vol. 10, pp. 921-87, 2007, FSU College of Law, Law and Economics Paper No. 07-25, FSU College of Law, Public Law Research Paper No. 287
Number of pages: 68 Posted: 01 Nov 2007 Last Revised: 01 May 2013
Accepted Paper Series
Florida State University - College of Law and Duke University School of Law
Downloads 1,165
8.

The Untold EpiPen Story: How Mylan Hiked Prices by Blocking Rivals

102 Cornell Law Review Online 53 (2017)
Number of pages: 20 Posted: 21 Sep 2016 Last Revised: 01 Feb 2017
Accepted Paper Series
Rutgers Law School and Independent
Downloads 1,092
9.

Pioneering Advantage in Generic Drug Competition

International Journal of Pharmaceutical and Healthcare Marketing 01/2014; 8(2)
Number of pages: 51 Posted: 20 Aug 2006 Last Revised: 05 Sep 2014
Accepted Paper Series
AIG and Cornell University - Samuel Curtis Johnson Graduate School of Management
Downloads 1,087
10.

Has the European Commission Become More Severe in Punishing Cartels? Effects of the 2006 Guidelines

Number of pages: 26 Posted: 11 Jan 2011 Last Revised: 27 Jan 2011
Working Paper Series
Purdue UniversityAmerican Antitrust Institute (AAI)
Downloads 1,054
11.

Business Model Innovation in the Pharmaceutical Industry: The Supporting Role of Organizational Design

Number of pages: 32 Posted: 25 Feb 2014
Working Paper Series
Copenhagen Business School - Department of Strategy and Innovation and Copenhagen Business School
Downloads 1,002
12.

Patent Trolling — Why Bio & Pharmaceuticals Are at Risk

17 Stan. Tech. L. Rev. 773, 2014, UC Hastings Research Paper No. 93
Number of pages: 40 Posted: 15 Feb 2014 Last Revised: 03 Apr 2016
Accepted Paper Series
UC Hastings Law and University of Michigan Law School
Downloads 954
13.

Competition and Regulation Issues in the Pharmaceutical Industry

Number of pages: 401 Posted: 30 Jul 2002
Working Paper Series
Australian Competition and Consumer Commission
Downloads 849
14.

Innovation for the 21st Century: Harnessing the Power of Intellectual Property and Antitrust Law

Oxford University Press, 2009
Number of pages: 16 Posted: 27 Mar 2009
Accepted Paper Series
Rutgers Law School
Downloads 829
15.

Access to Information and the Right to Health: The Human Rights Case for Clinical Trials Transparency

American Journal of Law and Medicine, Vol. 38, pp. 63-112, 2012
Number of pages: 50 Posted: 27 Sep 2011 Last Revised: 06 Mar 2015
Accepted Paper Series
University of Toronto - Faculty of Law and Independent
Downloads 823
16.

Diversification Strategy in the Pharmaceutical Industry

Number of pages: 20 Posted: 14 Oct 2008
Working Paper Series
"Alexandru Ioan Cuza" University of Iasi, Romania
Downloads 816
17.

Do National Patent Laws Stimulate Domestic Innovation in a Global Patenting Environment? A Cross-Country Analysis of Pharmaceutical Patent Protection, 1978-2002

Review of Economics and Statistics, Vol. 89, No. 3, 2007
Number of pages: 18 Posted: 28 Oct 2007 Last Revised: 08 Jun 2014
Accepted Paper Series
Downloads 791
18.

Asymmetric Social Interactions in Physician Prescription Behavior: The Role of Opinion Leaders

Stanford University Graduate School of Business Research Paper No. 1970
Number of pages: 41 Posted: 13 Oct 2006 Last Revised: 30 Jul 2014
Working Paper Series
Stanford University - Graduate School of Business, University of Michigan, Stephen M. Ross School of Business and affiliation not provided to SSRNRutgers, The State University of New Jersey - Rutgers Business School at Newark & New Brunswick
Downloads 786
19.

Cartel Overcharges and Optimal Cartel Fines

Number of pages: 16 Posted: 16 Nov 2007 Last Revised: 20 Nov 2007
Working Paper Series
University of Baltimore - School of Law and Purdue UniversityAmerican Antitrust Institute (AAI)

Multiple version iconThere are 2 versions of this paper

Downloads 775
20.

Pharmaceutical Marketing: Medical and Industry Biases

Journal of Pharmaceutical Finance, Economics & Policy, Forthcoming
Number of pages: 17 Posted: 04 Feb 2004
Accepted Paper Series
1350 Main St UNIT 1703
Downloads 754
21.

Counterfeit Drugs: The Good, the Bad and the Ugly

Albany Law Journal of Science and Technology, Vol. 15, 2006
Number of pages: 15 Posted: 30 Aug 2006
Accepted Paper Series
Boston University School of Law and affiliation not provided to SSRN
Downloads 751
22.

Corruption of Pharmaceutical Markets: Addressing the Misalignment of Financial Incentives and Public Health

Journal of Law, Medicine and Ethics, Forthcoming
Number of pages: 30 Posted: 28 Jun 2013 Last Revised: 24 Oct 2015
Accepted Paper Series
Carleton University - School of Public Policy and Administration
Downloads 739
23.

The Size of Cartel Overcharges: Implications for U.S. and E.U. Fining Policies

Number of pages: 40 Posted: 31 May 2007 Last Revised: 17 Sep 2008
Working Paper Series
Purdue UniversityAmerican Antitrust Institute (AAI) and University of Baltimore - School of Law
Downloads 723
24.

Some Accounting and Technical Problems with Antidumping Trade Cases Involving a Transition Economy: A Russian Case Study

Number of pages: 15 Posted: 12 Sep 2003
Working Paper Series
Fayetteville State University - Department of Accounting and Abu Dhabi University - Department of Accounting
Downloads 703
25.

Using Antitrust Law to Challenge Turing's Daraprim Price Increase

31 Berkeley Technology Law Journal 1379 (2017)
Number of pages: 30 Posted: 29 Jan 2016 Last Revised: 14 Jul 2017
Accepted Paper Series
Rutgers Law School, Program on Regulation, Therapeutics, and Law, Division of Pharmacoepidemiology and Pharmacoeconomics and Brigham and Women's Hospital/Harvard Medical School
Downloads 701
26.

A Real-World Analysis of Pharmaceutical Settlements: The Missing Dimension of Product-Hopping

Florida Law Review, Vol. 62, 2010
Number of pages: 28 Posted: 14 Apr 2010 Last Revised: 28 Dec 2013
Working Paper Series
Rutgers Law School
Downloads 697
27.

Consumer Protection in an Era of Globalization

IMPORT SAFETY: REGULATORY GOVERNANCE IN THE GLOBAL ECONOMY, Cary Coglianese, Adam Finkel & David Zaring, eds., University of Pennsylvania Press, 2009 , U of Penn, Inst for Law & Econ Research Paper No. 11-10
Number of pages: 20 Posted: 25 Mar 2011
Accepted Paper Series
University of Pennsylvania Law School, University of Michigan School of Public Health and University of Pennsylvania - Legal Studies Department
Downloads 697
28.

Impact of Profitability, R&D Intensity, and Cash Flow on R&D Expenditure in Pharmaceutical Companies

Number of pages: 13 Posted: 05 May 2011
Working Paper Series
Dexa Medica GroupDexa Laboratories of Biomolecular Sciences, Dexa Medica Group and Dexa Laboratories of Biomolecular Sciences, PT Dexa Medica
Downloads 696
29.

Two Puzzles Resolved: Of the Schumpeter - Arrow Stalemate and Pharmaceutical Innovation Markets

Iowa Law Review, Vol. 93, 2008
Number of pages: 58 Posted: 09 Apr 2007 Last Revised: 02 Jun 2013
Accepted Paper Series
Rutgers Law School
Downloads 696
30.

Synthesizing Law for Synthetic Biology

Minnesota Journal of Law, Science & Technology, Vol. 11, No. 2, pp. 629-65, 2010
Number of pages: 37 Posted: 25 Jun 2010
Accepted Paper Series
University of Kansas - School of Law
Downloads 691
31.

Countervailing Power in Wholesale Pharmaceuticals

Number of pages: 40 Posted: 25 Jul 2001
Working Paper Series
Massachusetts Institute of Technology (MIT) - Department of Economics and Dartmouth College - Department of Economics
Downloads 690
32.

Heterogeneous Learning and the Targeting of Marketing Communication for New Products

Number of pages: 43 Posted: 12 Oct 2006
Working Paper Series
Stanford Graduate School of Business and University of Michigan, Stephen M. Ross School of Business
Downloads 674
33.

Bidil: Race Medicine or Race Marketing?

Health Affairs, October 11, 2005
Number of pages: 9 Posted: 26 Oct 2005
Accepted Paper Series
University of Pennsylvania - Perelman School of Medicine and Northeastern University - School of Law
Downloads 664
34.

Effectiveness of Antitrust Sanctions on Modern International Cartels

Journal of Industry, Competition, and Trade 6 (2006): 195-223
Number of pages: 29 Posted: 31 May 2007 Last Revised: 09 Mar 2013
Accepted Paper Series
Purdue UniversityAmerican Antitrust Institute (AAI)
Downloads 659
35.

Global Competitiveness of Indian Pharmaceutical Industry: Trends and Strategies

ISID Working Paper No. 2006/05
Number of pages: 68 Posted: 02 Dec 2009
Working Paper Series
Sardar Patel Institute of Economic & Social ResearchCentral University of Gujarat

Multiple version iconThere are 2 versions of this paper

Downloads 645
36.

Marketing, Product Differentiation and Competition in the Market for Antiulcer Drugs

HBS Working Paper No. 01-014
Number of pages: 49 Posted: 23 Mar 2006
Working Paper Series
Greylock McKinnon Associates
Downloads 644
37.

Common Ownership and Market Entry: Evidence from Pharmaceutical Industry

DIW Berlin Discussion Paper No. 1738
Number of pages: 59 Posted: 26 Jun 2018 Last Revised: 17 Nov 2019
Working Paper Series
KU Leuven, KU Leuven - Faculty of Business and Economics (FEB) and City University London - Department of EconomicsUniversitat Pompeu Fabra - Department of Economics and Business (DEB)
Downloads 638
38.

Forecasting Market Share in the US Pharmaceutical Market

Nature Reviews Drug Discovery. 2015. Vol. 14, No. 9: 594-595
Number of pages: 19 Posted: 18 Apr 2016
Accepted Paper Series
Novartis International AG and Duke University - Fuqua School of Business
Downloads 632
39.

Complicated Compulsory Licenses: The Waiver/Article31bis 'Solution'

Cynthia M. Ho, ACCESS TO MEDICINE IN THE GLOBAL ECONOMY: INTERNATIONAL AGREEMENTS ON PATENTS AND RELATED RIGHTS, Oxford University Press, April 2011, Loyola University Chicago School of Law Research Paper No. 2011-032
Number of pages: 27 Posted: 05 Sep 2011
Accepted Paper Series
Loyola University of Chicago School of Law
Downloads 628
40.

The United States Department of Justice Antitrust Division's Cartel Enforcement: Appraisal and Proposals

American Antitrust Institute Working Paper No. 08-02
Number of pages: 93 Posted: 08 May 2008 Last Revised: 22 May 2009
Working Paper Series
Purdue UniversityAmerican Antitrust Institute (AAI)
Downloads 624
41.

Global Antitrust Prosecutions of International Cartels: Focus on Asia

Number of pages: 34 Posted: 07 Nov 2007 Last Revised: 20 Apr 2009
Working Paper Series
Purdue UniversityAmerican Antitrust Institute (AAI)
Downloads 610
42.

REACHing Asia Continued

Number of pages: 13 Posted: 18 Sep 2009
Working Paper Series
Ghent University - Faculty of Law
Downloads 603
43.

What is 'Business Development'? The Case of Biotechnology

Schmalenbach Business Review, Vol. 59, April 2007
Number of pages: 25 Posted: 04 Aug 2007
Accepted Paper Series
affiliation not provided to SSRN and affiliation not provided to SSRN
Downloads 601
44.

Quantifying the Benefits of Individual Level Targeting in the Presence of Firm Strategic Behavior

Number of pages: 50 Posted: 17 Oct 2006
Working Paper Series
Santa Clara University, University of Michigan, Stephen M. Ross School of Business and University of Chicago
Downloads 582
45.

Determinants of the Round-to-Round Returns to Pre-Ipo Venture Capital Investments in U.S. Biotechnology Companies

Number of pages: 44 Posted: 08 Jan 2004
Working Paper Series
University of North Carolina Kenan-Flagler Business School
Downloads 578
46.

Ownership Vs. Contract: How Vertical Integration Affects Investment Decisions in Pharmaceutical R&D

McCombs Research Paper Series No. FIN-01-06, AFA 2006 Boston Meetings Paper
Number of pages: 56 Posted: 07 Mar 2005 Last Revised: 08 Feb 2014
Working Paper Series
Bates White, LLC

Multiple version iconThere are 2 versions of this paper

Downloads 570
47.

Can Compulsory Licensing Improve Access to Essential Medicines?

Number of pages: 21 Posted: 23 Apr 2008
Working Paper Series
University of Connecticut - School of Business
Downloads 566
48.

The Indian Pharmaceutical Industry - Fundamentals vis-a-vis Market Perception

Number of pages: 23 Posted: 08 Mar 2009
Working Paper Series
Calcutta Business School and ICFAI Business School
Downloads 566
49.

New Drug Development: Estimating Entry from Human Clinical Trials

FTC Bureau of Economics Working Paper No. 262
Number of pages: 24 Posted: 12 Sep 2003
Working Paper Series
CBO and Federal Trade Commission - Bureau of Economics
Downloads 561
50.

Cartel Amnesties Granted: Worldwide Whistleblowers

Number of pages: 26 Posted: 21 Oct 2008
Working Paper Series
Purdue UniversityAmerican Antitrust Institute (AAI)
Downloads 559